Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tatiana A. Prikazchikova"'
Autor:
Vera S. Shashkovskaya, Polina I. Vetosheva, Arina G. Shokhina, Ilya O. Aparin, Tatiana A. Prikazchikova, Arsen S. Mikaelyan, Yuri V. Kotelevtsev, Vsevolod V. Belousov, Timofei S. Zatsepin, Tatiana O. Abakumova
Publikováno v:
Biomedicines, Vol 11, Iss 7, p 1783 (2023)
Reactive oxygen species (ROS) are highly reactive products of the cell metabolism derived from oxygen molecules, and their abundant level is observed in many diseases, particularly tumors, such as hepatocellular carcinoma (HCC). In vivo imaging of RO
Externí odkaz:
https://doaj.org/article/351f4c6f437349af9b0647befbdc787f
Autor:
Alena Y. Streletskaia, Viacheslav V. Senichkin, Tatiana A. Prikazchikova, Timofei S. Zatsepin, Boris Zhivotovsky, Gelina S. Kopeina
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 8 (2020)
As an important regulator of apoptosis, Mcl-1 protein, a member of the Bcl-2 family, represents an attractive target for cancer treatment. The recent development of novel small molecule compounds has allowed Mcl-1-inhibitory therapy to proceed to cli
Externí odkaz:
https://doaj.org/article/fe281dc5d1934d109ba17179daeb6267
Autor:
Viacheslav V. Senichkin, Nikolay V. Pervushin, Alexey V. Zamaraev, Elena V. Sazonova, Anton P. Zuev, Alena Y. Streletskaia, Tatiana A. Prikazchikova, Timofei S. Zatsepin, Olga V. Kovaleva, Elena M. Tchevkina, Boris Zhivotovsky, Gelina S. Kopeina
Publikováno v:
Cancers, Vol 14, Iss 1, p 181 (2021)
BH3 mimetics represent a promising tool in cancer treatment. Recently, the drugs targeting the Mcl-1 protein progressed into clinical trials, and numerous studies are focused on the investigation of their activity in various preclinical models. We in
Externí odkaz:
https://doaj.org/article/4d20d04e09eb46a3a7f13559f0a60005
Autor:
Victoria V Smirnova, Ekaterina D Shestakova, Daria S Nogina, Polina A Mishchenko, Tatiana A Prikazchikova, Timofei S Zatsepin, Ivan V Kulakovskiy, Ivan N Shatsky, Ilya M Terenin
Publikováno v:
Nucleic Acids Research
eIF4G2 (DAP5 or Nat1) is a homologue of the canonical translation initiation factor eIF4G1 in higher eukaryotes but its function remains poorly understood. Unlike eIF4G1, eIF4G2 does not interact with the cap-binding protein eIF4E and is believed to
Autor:
Kopeina, Viacheslav V. Senichkin, Nikolay V. Pervushin, Alexey V. Zamaraev, Elena V. Sazonova, Anton P. Zuev, Alena Y. Streletskaia, Tatiana A. Prikazchikova, Timofei S. Zatsepin, Olga V. Kovaleva, Elena M. Tchevkina, Boris Zhivotovsky, Gelina S.
Publikováno v:
Cancers; Volume 14; Issue 1; Pages: 181
BH3 mimetics represent a promising tool in cancer treatment. Recently, the drugs targeting the Mcl-1 protein progressed into clinical trials, and numerous studies are focused on the investigation of their activity in various preclinical models. We in